ERBB2 and non-small cell lung carcinoma: The clinical benefit of T-DXd at doses of 6.4 mg/kg was demonstrated in a phase II DESTINY-Lung01 trial (cohort 2 including 91 patients with HER2 MUT NSCLC), which reported an ORR of 54.9%, mPFS of 8.2 months (95% CI, 6.0–11.9), and mOS of 17.8 months (95% CI, 13.8–22.1).